What is Platelet-Rich Plasma (PRP)?

An Advanced Overview for Medical Practitioners

Biological Basis of PRP

Platelet-Rich Plasma (PRP) is an autologous biologic product derived from the patient’s own whole blood. It contains a supraphysiological concentration of platelets suspended in plasma, enriched with growth factors, cytokines, and extracellular vesicles that modulate inflammation, stimulate cellular proliferation, and enhance tissue regeneration.

The average baseline platelet count in human peripheral blood is ~200,000 ± 75,000/µL. In whole blood, platelets remain in a quiescent state, with an in vivo half-life of approximately 7–10 days. Upon activation by exposure to collagen, thrombin, or calcium ions, platelets release their intracellular alpha and dense granule contents in a controlled, sequenced manner.

Key Bioactive Constituents of PRP

Most of PRP’s regenerative capacity is mediated by molecules stored in platelet alpha granules, including:

Growth Factor Abbreviation Primary Function
Platelet-Derived Growth Factor PDGF Chemotaxis and proliferation of fibroblasts, smooth muscle cells, and osteoblasts; ECM production
Transforming Growth Factor Beta TGF-β ECM production, collagen synthesis, modulation of inflammation
Vascular Endothelial Growth Factor VEGF Angiogenesis, endothelial cell migration and proliferation
Epidermal Growth Factor EGF Epithelial cell proliferation and differentiation
Fibroblast Growth Factor FGF Stimulation of mesenchymal cell growth and differentiation
Insulin-like Growth Factor 1 IGF-1 Promotes cell growth, survival, and collagen synthesis

Upon activation, over 95% of platelet-stored growth factors are released within 10 minutes, initiating a cascade of biological events essential for soft tissue repair and regeneration.

The Phases of PRP-Mediated Healing

PRP accelerates and enhances the body’s intrinsic healing cascade, particularly in poorly vascularised tissues. The three primary overlapping phases are:

1. Inflammation (Days 1–3)

  • Platelet degranulation triggers clot formation and release of pro-inflammatory cytokines

  • Neutrophil and macrophage recruitment facilitates debridement and release of further mediators (IL-1β, TNF-α, MCP-1)

  • Dense granules release ADP, serotonin, and calcium to promote platelet aggregation and vascular constriction

2. Proliferation (Days 3–21)

  • Proliferation and migration of fibroblasts, endothelial cells, and keratinocytes

  • Type III collagen deposition

  • Neoangiogenesis via VEGF, FGF, and TGF-β signalling

  • Epithelialisation and granulation tissue development

3. Remodelling (Weeks to Months)

  • Type III collagen is replaced with Type I

  • Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) regulate ECM turnover

  • Vascular maturation and functional restoration of tissue

The Importance of Platelet Concentration

The regenerative efficacy of PRP is directly correlated with the dose of functional platelets delivered to the target tissue. Therapeutic PRP must meet or exceed baseline platelet counts to elicit a clinically relevant biological effect.

Alocuro Evidence-Based Targets:

  • Aesthetic applications: 3–5× baseline concentration

  • Orthopaedics/MSK: 6–9× baseline

  • Surgical/wound healing: varies by application and tissue type

However, many commercial PRP kits:

  • Achieve only ~2× baseline platelet concentration due to plasma dilution

  • Recover only ~60% of total platelets

  • Include residual red blood cells and neutrophils, which may exacerbate inflammation

PRP Clinical Applications – Mechanisms & Context

Musculoskeletal Medicine

  • PRP improves tendon matrix organisation and fibroblast proliferation

  • Reduces IL-6 and TNF-α expression in osteoarthritic joints

  • Increases hyaluronic acid synthesis and modulates chondrocyte phenotype

  • Common sites: rotator cuff, lateral epicondyle, patellar tendon, Achilles tendon, plantar fascia, intra-articular joints

Aesthetic & Dermatology

  • Enhances dermal fibroblast activity and ECM production

  • Modulates melanogenesis, aiding in pigmentation control

  • Induces angiogenesis in hypoperfused skin regions

  • Supports follicular cell proliferation in androgenetic alopecia and hypotrichosis

Wound Care

  • Increases VEGF and angiopoietin-1 expression

  • Accelerates epithelial closure and granulation tissue formation

  • Reduces microbial load through leukocyte-derived antimicrobial peptides

Surgical Use

  • Promotes haemostasis via thrombin-mediated clot reinforcement

  • Reduces incidence of post-operative seroma and infection

  • Enhances graft integration and suture line healing

Why Clinicians Choose Alocuro

  • Consistent concentration and yield across patients

  • Customisable protocols for LP-PRP and LR-PRP

  • ARTG-listed with full practitioner support

  • Scalable across aesthetic, musculoskeletal, and surgical practices

  • Ongoing education and clinical case consultation provided

Parameter Alocuro PRO-PRP
Platelet Recovery Efficiency 90–95%
Concentration Range Up to 12× baseline
Plasma Yield Options Adjustable from 10–25% of whole blood
Leukocyte Modulation LP-PRP or LR-PRP selectable
Processing Time 7 minutes
Volume Formats 10ml, 15ml, 20ml, 30ml, 60ml
Centrifuge Compatibility AL1015 (small kits) / AL416 (all sizes)
Regulatory Status ARTG-listed, ISO 13485-certified

Get in touch to explore how Alocuro can elevate your practice

Contact Us